Climb Bio Statistics
Total Valuation
Climb Bio has a market cap or net worth of $285.68 million. The enterprise value is $62.64 million.
Market Cap | 285.68M |
Enterprise Value | 62.64M |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024, after market close.
Earnings Date | Nov 12, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Climb Bio has 67.06 million shares outstanding. The number of shares has increased by 6.18% in one year.
Shares Outstanding | 67.06M |
Shares Change (YoY) | +6.18% |
Shares Change (QoQ) | +9.81% |
Owned by Insiders (%) | 0.73% |
Owned by Institutions (%) | 27.24% |
Float | 26.24M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.28 |
P/FCF Ratio | 5,011.86 |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | 1,098.88 |
Financial Position
The company has a current ratio of 60.41, with a Debt / Equity ratio of 0.00.
Current Ratio | 60.41 |
Quick Ratio | 59.65 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | 1.75 |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -38.35% and return on invested capital (ROIC) is -25.04%.
Return on Equity (ROE) | -38.35% |
Return on Assets (ROA) | -24.54% |
Return on Capital (ROIC) | -25.04% |
Revenue Per Employee | n/a |
Profits Per Employee | -$5.84M |
Employee Count | 11 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +66.41% in the last 52 weeks. The beta is -0.38, so Climb Bio's price volatility has been lower than the market average.
Beta (5Y) | -0.38 |
52-Week Price Change | +66.41% |
50-Day Moving Average | 6.17 |
200-Day Moving Average | 5.58 |
Relative Strength Index (RSI) | 27.33 |
Average Volume (20 Days) | 412,353 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -67.21M |
Pretax Income | n/a |
Net Income | -64.20M |
EBITDA | n/a |
EBIT | -67.21M |
Earnings Per Share (EPS) | -$2.28 |
Balance Sheet
The company has $223.14 million in cash and $100,000 in debt, giving a net cash position of $223.04 million or $3.33 per share.
Cash & Cash Equivalents | 223.14M |
Total Debt | 100,000 |
Net Cash | 223.04M |
Net Cash Per Share | $3.33 |
Equity (Book Value) | 222.28M |
Book Value Per Share | 3.33 |
Working Capital | 222.26M |
Cash Flow
Operating Cash Flow | 57,000 |
Capital Expenditures | n/a |
Free Cash Flow | 57,000 |
FCF Per Share | $0.00 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Climb Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -6.18% |
Shareholder Yield | -6.18% |
Earnings Yield | -22.47% |
FCF Yield | 0.02% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 3 |